MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Cryoport and Sanaria Expand Logistics Partnership Supporting Malaria Vaccines distributed in Liquid Nitrogen Vapor Phase;
Cryoport, Inc., the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers and reproductive medicine, today announced that the Company is enhancing its cryogenic logistics support of its Sanaria partnership, which includes Sanaria’s production of malaria vaccine as well as its research and development efforts.
Sanaria recognized as a NIH SBIR/STTR Notable Success
“NIH SBIR funding provided Sanaria with critical early-stage dollars to get our lead vaccine off the ground. Without this funding, Sanaria would have never gotten started and our malaria vaccine would not exist. No other investor would have provided money for this type of high-risk research.” – Dr. Steve Hoffman, CEO of Sanaria Read the full NIH SBIR story!
First controlled human malaria infection in Africa shows that PfSPZ Challenge can be used for drug and vaccine development in the field
The innovative PfSPZ Challenge is key to success for speedier testing of new malaria vaccine and drugs.
Explainer: GSK submits to EMA; Sanaria takes different approach
GSK submitted a regulatory application to the European Medicines Agency for its malaria vaccine candidate, RTS,S. Sanaria and GSK's different approaches are explained in this Wall Street Journal article.
Sanaria’s CEO & CSO, Dr. Stephen L. Hoffman, ranked 3rd out of the 50 most influential people in vaccines behind Bill Gates and Dr. Thomas Monath
See the full report from Vaccine Nation!
Sanaria Inc. To Launch Crowdfunding Campaign For Sporobottm, A Mosquito-Dissecting Robot For Accelerating Manufacture Of Sanaria’s Malaria Vaccine
Biotechnology company Sanaria Inc. aims to raise at least $250,000 in 30 days on Indiegogo.com, a crowdfunding website. The campaign launches on May 6, 2014. Funds will be dedicated to the development of SporoBotTM, a robot that will dissect mosquito salivary glands. By replacing manual microdissection of mosquito salivary glands, SporobotTM will automate a key step in the manufacturing process of Sanaria® PfSPZ Vaccine against malaria.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.